Menu
Česky English Deutsch
+420 532 23 1111

Mgr. Marek Borský

Vzdělání

1997 - Mgr. -  Molekulární biologie, PřF MU Brno

2008 - atestace "Vyšetřovací metody v klinické hematologii"

Pozice

1997 - 2002  Výzkumný ústav zdraví dítěte

2002 - dodnes, JOP s VŠ, Centrum molekulární biologie a genové terapie, IHOK, FN Brno

2011 - dodnes, vedoucí sekce průtokové cytometrie, Centrum molekulární biologie a genové terapie, IHOK, FN Brno

        Členství

Česká společnost pro analytickou cytometrii

Česká hematologická společnost

Vybrané publikace (2014 - 2019)

1.      Boudny M, Zemanova J, Khirsariya P, Borsky M, Verner J, Cerna J, et al. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica. 2019 Apr 11;haematol.2018.203430.

2.      Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, et al. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. Leukemia. 2018 Jul 20;

3.      Kantorova B, Malcikova J, Brazdilova K, Borsky M, Plevova K, Smardova J, et al. Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients. Br J Haematol. 2017 Sep;178(6):979–82.

4.      Brazdilova K, Plevova K, Skuhrova Francova H, Kockova H, Borsky M, Bikos V, et al. Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL. Leukemia [Internet]. 2017 Sep 22 [cited 2017 Sep 25]; Available from: http://www.nature.com.ezproxy.muni.cz/leu/journal/vaop/ncurrent/full/leu2017274a.html?foxtrotcallback=true

5.      Zemanova J, Hylse O, Collakova J, Vesely P, Oltova A, Borsky M, et al. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. Oncotarget [Internet]. 2016 Aug 19 [cited 2016 Sep 6];5(0). Available from: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=11388

6.      Poppova L, Janovska P, Plevova K, Radova L, Plesingerova H, Borsky M, et al. Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. Br J Haematol. 2016 Sep 1;n/a-n/a.

7.      Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 Sep 22;128(12):1609–13.

8.      Kantorova B, Malcikova J, Brazdilova K, Borsky M, Plevova K, Smardova J, et al. Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients. Br J Haematol. 2016 Jul 29;

9.      Janovska P, Poppova L, Plevova K, Plesingerova H, Behal M, Kaucka M, et al. Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 2016 Jan 15;22(2):459–69.

10.    Culen M, Borsky M, Nemethova V, Razga F, Smejkal J, Jurcek T, et al. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. Oncotarget. 2016 Apr 29;7(22):33016–24.

11.    Janovska P, Poppova L, Plevova K, Plesingerova H, Behal M, Kaucka M, et al. Autocrine signaling by Wnt-5a deregulates chemotaxis of leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia. Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. 2015 Aug 3;

12.    Sebejova L, Borsky M, Jaskova Z, Potesil D, Navrkalova V, Malcikova J, et al. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab. Experimental Hematology. 2014 Oct;42(10):867-74.e1.

13.    Potěšil D, Stejskal S, Borský M, Šimara P, Havelková M, Rázga F, et al. Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry. Analytical Letters. 2014 Apr 13;47(6):944–57.

14.    Musilova M( 1 ), Razga F( 1 2 ), Jurcek T( 1 ), Jeziskova I( 1 ), Borsky M( 1 ), Nemethova V( 1 2 ), et al. BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing. American Journal of Hematology. 2014 01;89(10):1016–7.

15.    Jurcek T( 1 ), Razga F( 1 2 ), Mazancova P( 1 ), Dvorakova D( 1 3 ), Borsky M( 1 ), Zackova D( 1 ), et al. Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia. Leukemia and Lymphoma. 2014 01;55(8):1915–7.

Ke stažení
Informace o pohotovosti v Brně a Jihomoravském kraji